Tavexia Lifecare has announced a strategic foray into the pharmaceutical sector by acquiring a 60% stake in Thane-based Meyonex Pharmaceuticals for Rs 67.19 crore. The deal involves purchasing fresh equity at Rs 32 per share. To fund this expansion, Tavexia has received in-principle approval to raise capital through equity, warrants, or debt instruments. Shareholders should watch for further updates on the fund-raising structure and potential equity dilution impacts.
Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals
Investment Amount: Rs 67.19 crore | Acquisition Price: Rs 32 per share
Reader Takeaway: Strategic entry into pharma sector; potential equity dilution remains a key factor for shareholders to watch.
What just happened
Tavexia Lifecare Limited has officially approved the acquisition of a 60% stake in Meyonex Pharmaceuticals Limited, an unlisted public company based in Thane. Tavexia will subscribe to 2,09,97,180 fresh equity shares at a price of Rs 32 per share. The transaction will be settled entirely in cash, leaving the remaining 40% equity in the hands of Meyonex’s existing shareholders.
Why this matters
This move marks a significant shift for Tavexia Lifecare, diversifying its business operations into the pharmaceutical industry. By acquiring a majority stake, the company gains control over Meyonex, which reported a turnover of Rs 10.79 crore for FY 2025. This allows Tavexia to integrate pharmaceutical manufacturing or distribution capabilities directly into its corporate structure.
What changes now
The Board of Tavexia has provided in-principle approval for a fundraising exercise to facilitate this deal. Options under consideration include the issuance of equity shares, warrants, or various debt securities. While the specific scale and timing of the fundraising are yet to be decided, investors should prepare for potential changes to the company's capital structure.
What to track next
Shareholders should monitor subsequent regulatory filings regarding the finalization of definitive agreements and the specific modalities of the fundraising. The impact of any potential equity dilution on current EPS will be a crucial point of focus for retail investors as the details emerge.